Hengrui Medicine: HRS-2162 Injection Receives Drug Clinical Trial Approval Notification Letter

Hengrui Medicine announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received the approval notice for the drug clinical trial of HRS-2162 injection issued by the National Medical Products Administration. Clinical trials will be conducted in the near future. HRS-2162 injection is a new generation of muscle relaxant antagonist that can counteract the pharmacological effects of muscle relaxants and rapidly restore muscle tone. Currently, there are no similar products approved for marketing domestically or internationally. As of now, the total research and development investment for the HRS-2162 injection project is approximately 28.25 million yuan.